{"id":4399,"date":"2026-11-15T09:00:00","date_gmt":"2026-11-15T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4399"},"modified":"2026-11-18T21:45:38","modified_gmt":"2026-11-19T01:45:38","slug":"fda-rejects-ivonescimab-filing-over-evidence-portability","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4399","title":{"rendered":"FDA Rejects Ivonescimab Filing Over Evidence Portability"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4404\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Summit_Ivonescimab_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Summit Therapeutics (Akeso licensor)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA complete response letter (previously missed 15 Nov disclosure)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>PD-1\u00d7VEGF bispecific antibody<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Ivonescimab (AK112, SMT112)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>PD-1; VEGF<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>EGFR-mutant non-small-cell lung cancer after EGFR TKI<\/p>\n<h4>Summary<\/h4>\n<p>FDA issued a complete response letter for Summit\u2019s ivonescimab plus chemotherapy application in EGFR-mutant non-small-cell lung cancer after EGFR-targeted treatment. The public letter says substantial evidence of effectiveness and a favorable benefit\u2013risk profile were not established: 93% of 275 progression-free-survival events occurred in China, final overall survival was not statistically significant, and the PFS improvement was modest for an add-on regimen.<\/p>\n<p>The letter is electronically dated November 13; Summit disclosed receipt November 15, after the prior Insilens archive. FDA said 257 of 275 PFS events arose in Chinese patients and that US applicability was not established. It also cited little ORR difference and added immune and VEGF-related toxicity. FDA recommended a new adequate, well-controlled multiregional study and a meeting on design. The letter is a rejection of this application, not a global invalidation of ivonescimab or a finding that the drug lacks any activity.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> the US filing strategy failed because regional evidence, modest PFS and absent statistically significant OS did not support the additional toxicity burden.<\/p>\n<p><strong>Interpretation B:<\/strong> the molecule may still have benefit in other indications or a prospectively global design; exploratory regional follow-up cannot rescue this application but does not exclude future success. The dominant issue is both clinical magnitude and transportability: enrollment began in China long before North America and Europe, with differential data cutoff dates. Post-hoc regional analyses are exploratory. A new study may need a clinically meaningful OS, PFS or other accepted endpoint with balanced geographic representation and robust safety. The CRL does not establish motives for the sponsor\u2019s trial design.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Ivonescimab, AK112 or SMT112, is a PD-1\u00d7VEGF bispecific antibody from Akeso licensed to Summit in selected territories. It aims to block immune inhibition and angiogenic signaling. The rejected application paired it with platinum chemotherapy after EGFR TKI therapy.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>FDA\u2019s public CRL independently substantiates the reasons, beyond the company summary.<\/li>\n<li>Missing: full patient-level regional outcomes, subsequent trial plan and timeline.<\/li>\n<li>Upgrade: FDA-aligned multiregional trial with meaningful endpoint and tolerable toxicity.<\/li>\n<li>Downgrade: inability to reproduce benefit outside China.<\/li>\n<li>Falsifier of a broad molecule-failure thesis: convincing randomized benefit in another setting.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a major negative US regulatory signal for the filed indication and a concrete warning about global portability of China-heavy oncology datasets, not a verdict on all PD-1\u00d7VEGF bispecifics.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: negative. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA issued a complete response letter for Summit\u2019s ivonescimab plus chemotherapy application in EGFR-mutant non-small-cell lung cancer after EGFR-targeted treatment. The public letter says substantial evidence of effectiveness and a favorable benefit\u2013risk profile were&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4404,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1542,521,169],"class_list":["post-4399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-egfr-mutant-nsclc-2","tag-ivonescimab","tag-summit-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4399"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4399\/revisions"}],"predecessor-version":[{"id":4425,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4399\/revisions\/4425"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4404"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}